The Wistar Institute Cancer Center presents four Type I Shared Resources in this application: Animal Facility, Flow Cytometry, Imaging, and Protein Expression. During the past project period the Cancer Center made substantial investments in the Type I Shared Resources, utilizing over $7.2 million in capital funds and equipment grants for equipment upgrades and facility improvements. These Resources function as engines, integrated components ofthe research being conducted by Cancer Center members. The Type I Resources have demonstrated a significant impact to the scientific objectives ofthe Cancer Center, contributing to 172 of 382 (45%) of the unique cancer-related publications reported by the three scientific Programs. Following a comprehensive realignment of its Shared Resources by the appointment of dedicated leadership as described in the Cancer Center Administration section of this application, Shared Resources were grouped as Type I or Type II reflecting the intensity of collaborative input of their services. Type I Shared Resources provide critical and well-defined services that require an initial consultation followed by the delivery of time/format-defined services. Collaborative input for the type of service and data analysis is often required through consultation, yet such services generally achieve or are close in achieving full recovery of operating costs through chargebacks. Clear benchmarks and objective review criteria were introduced in order to enable timely oversight, scientific impact, quality of service, and financial strength for each Shared Resource. Regular evaluations of scientific impact for the Cancer Center (i) and sustainability of services (ii) for each resource guide the decision-making process for the Shared Resources. Overall Type I Shared Resources provide an essential cornerstone for research as their impact on discovery is inherent to the reliability, innovation, and state-of-the-art service platforms delivered.

Public Health Relevance

The deployment of state-of-the-art, technologically advanced scientific capabilities has become an indispensable requirement to conduct modern cancer research. Type I Shared Resources fulfill this need by providing well-defined, personalized service to Wistar Cancer Center investigators in support of their interprogrammatic and multidisciplinary research programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8690265
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$258,701
Indirect Cost
$116,941
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications